北京清辉联诺生物科技有限责任公司-Unicet Biotech

About 北京清辉联诺生物科技有限责任公司-Unicet Biotech

Beijing Qinghui Liannuo Biotechnology Co., Ltd., referred to as Qinghui Liannuo, is a biotechnology company dedicated to the development of innovative immunotherapies. The company has established three research and development pipelines: gamma delta T cell therapy, targeted drugs, and novel vaccine adjuvants. Its products are expected to achieve breakthroughs in the treatment of solid tumors, infectious diseases, autoimmune diseases, and vaccine development. Related research results have been published in internationally renowned academic journals such as Cell and Immunity. The company has established good cooperative relationships with several well-known drug and vaccine development companies and is rapidly advancing the translation of projects from laboratory to industry. Founded in September 2018, the company completed a pre-A round of financing of 100 million yuan in November 2021, led by a well-known pharmaceutical fund. The company's first cell therapy product has entered the investigator-initiated clinical research stage, and multiple R&D projects have received support from the National Key R&D Program and Beijing Science and Technology Plan projects. The company has been selected as a National High-tech Enterprise, Zhongguancun High-tech Enterprise, and Zhongguancun Golden Seed Enterprise. The company's founder, Dr. Zhang Yonghui, is a tenured researcher and doctoral supervisor at the School of Pharmaceutical Sciences, Tsinghua University, and has been selected for the "Overseas High-level Talents" program by the Organization Department of the CPC Central Committee, is an Education Ministry Changjiang Scholar, and a recipient of the Shulan Medical Award. Co-founder and CEO Dr. Zhao Hui holds dual bachelor's degrees in Biology and Business Administration from the University of Science and Technology of China, a doctorate from Tsinghua University, and was a visiting scholar at Harvard University. He has been selected for the "Chuangqing" Zhongguancun U30 program. Co-founder and CTO Dr. Ma Weiwei holds bachelor's and master's degrees in Biology from Tsinghua University and a doctorate in Immunology from Imperial College London. He has over 10 years of experience in immunology research and has been selected for the "Zhongguancun Young Talent" program. Upon joining Qinghui Liannuo, you will have a dedicated mentor to tailor a training plan for you, access to 2000 square meters of standardized and comfortable office and laboratory space to showcase your talents, and a vibrant team to share in both the struggles and successes. The company is in a period of rapid development and is eager to have outstanding individuals join us soon. In the future, the company will issue stock options based on the job level system and individual contributions. Come and fight alongside us to achieve financial freedom early! Mission: Enable humanity to enjoy a better life journey. Vision: Become a pioneer and leader in gamma delta T cell-related immunotherapy. Core Values: Reverence for Life, Virtue and Perseverance, Innovation and Change.